Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.5% - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares fell 3.5% on Friday . The stock traded as low as $0.29 and last traded at $0.30. 25,356,621 shares were traded during mid-day trading, a decline of 38% from the average session volume of 41,203,656 shares. The stock had previously closed at $0.31.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a market capitalization of $57.94 million, a PE ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The business has a 50-day simple moving average of $0.24 and a 200-day simple moving average of $0.36.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.